American Society of Hirudotherapy

The pharmacology of extinction

Review published in Journal of ethnopharmacology (1992)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentHuxtable RJ · Journal of ethnopharmacology, 1992

Abstract

It is impossible to predict what compounds of pharmacological interest may be present in an unexamined species. The extinction of such species may result, therefore, in the loss of therapeutically significant compounds. The fact that science will never know what has been lost does not lessen the significance of the loss. A number of species are discussed to exemplify the potential loss. Ginkgo biloba is an ancient plant, apparently saved from a natural extinction by human intervention. From this tree, the ginkgolides have been isolated. These are potent inhibitors of platelet activating factor and hold promise in the treatment of cerebral ischemia and brain edema. Two species, the tree Taxus brevifolia and the leech Hirudo medicinalis, are threatened as a result of human activity. Both have recently yielded complex compounds of therapeutic importance. The antitumor agent, taxol, is obtained from T. brevifolia and the thrombin inhibitor, hirudin, is found in H. medicinalis. Catharanthus roseus, source of the anticancer agents vincristine and vinblastine, although not threatened, derives from a largely unexamined but severely stressed ecosystem of some 5000 plant species. In other examples, ethnobotanical knowledge of certain plants may be lost while the species survive, as exemplified by the suppression of the Aztec ethnobotany of Mesoamerica by the invading Spanish. Finally, the fallacy of the 'snail darter syndrome', where species may be viewed as too insignificant to worry about, is exposed by consideration of the pharmacological activities of a sea hare (a shell-less marine mollusc) and various leeches.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsEcologyMedicine, TraditionalPlants, MedicinalTissue Extracts

Summary

It is impossible to predict what compounds of pharmacological interest may be present in an unexamined species.

Why This Matters for Hirudotherapy

This review discusses how species extinction may result in the loss of therapeutically significant compounds, citing multiple examples including Ginkgo biloba (ginkgolides), Taxus brevifolia (taxol), Catharanthus roseus (vincristine, vinblastine), and the leech Hirudo medicinalis (hirudin). It identifies H. medicinalis as a species threatened by human activity that has yielded hirudin, a thrombin inhibitor of therapeutic importance, and references the pharmacological activities of various leeches as further examples. For ASH's domain, this is relevant insofar as it frames medicinal leeches as a source of bioactive therapeutics and underscores the conservation significance of leech biodiversity. The caveat is that this is a broad narrative review rather than an empirical study, and it provides no original data on hirudotherapy or leech-derived compounds beyond hirudin.

Citation

The pharmacology of extinction

Huxtable RJ · Journal of ethnopharmacology, 1992

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.